MC2 Biotek has received positive results from a plaque psoriasis study comparing MC2-01 PAD™ Cream (fixed dose combination of Betamethasone dipropionate/calcipotriene) to vehicle, monads, Taclonex Ointment and Taclonex Topical Suspension.
Data clearly demonstrates the potential of the MC2-01 PADTM Cream to fully release the potential of API’s and that the MC2-01 PAD™ Cream has the potential to become a leading topical drug for treatment of mild to moderate psoriasis.
The MC2-01 PAD™ Cream is an cosmetically elegant cream that is easy to spread and vanishes quickly after application. This will improve compliance and the quality of life of patients thereby addressing a clear unmet clinical need.
Copenhagen, May 2015
BACK
